Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 21 Parkinson's papers of 5,088 | 0.59 |
| pathways Reactome | 12 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4134
Sealed predictions
- HGS in dopamine neurons, braak+0.29 (p 0.442) → -0.63 (p 0.068)receipt 4141
Swarm cases
receipt 4141: HGS in dopamine neurons, braak
- power
- full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.243, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.261, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.18, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.73 (p 6.2e-4, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HGS in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up HGS · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.73 p 0.0100 (needs p < 4.7e-4)
Receipts
loading the receipts